Dynavax's Flu Vaccine Shows Immunity to Divergent and Potentially Pandemic Flu Strains in Preclinica
Dynavax Technologies Corp., a biopharmaceutical company specializing in treatments for allergies, infectious and chronic inflammatory diseases, said Monday preclinical data indicates its flu vaccine confers immunity to "widely divergent" strains of the flu and has potential to be a universal flu vaccine.
Tags : health--fitness flu dynavax influenza h5n1 avian news
You will be redirected to Dynavax's Flu Vaccine Shows Immunity to Divergent and Potentially Pandemic Flu Strains in Preclinica, in 20 seconds.